Company / Debt per Share
Gain Therapeutics, Inc. Debt per Share History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Debt per Share
$0.02
FY2024
5-year range
$0.02 / $0.17
FY2021-FY2024
Trend
-46.4%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Debt per Share has declined for 3 consecutive years, from $0.17 in FY2021 to $0.02 in FY2024.
Based on SEC 10-K filings.
0.02 in FY2024 with a 3-year CAGR of -50.5%.
Improved from $0.04 to $0.02 over the past 2 years.
Debt per Share over time
Growth rates
- 3-Year CAGR
- -50.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Gain Therapeutics, Inc.'s debt per share has declined for 3 consecutive years.
- In FY2024, debt per share decreased 46.4% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -16.87 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Debt per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $0.02 | -46.4% |
| FY2023 | $0.04 | -9.3% |
| FY2022 | $0.04 | -75.0% |
| FY2021 | $0.17 | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026